Monday, November 25, 2024
HomeTagsSIRPα immuno-oncology program

SIRPα immuno-oncology program

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

Boehringer Ingelheim and OSE Immunotherapeutics SA (OSE), a clinical stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics